Global Neoantigen Peptides Manufacturing Market is projected to grow at a compound annual growth rate (CAGR) of 16.4% from 2022 to 2030. Neoantigens are newly generated peptides that are capable of inducing tumour-specific T cell recognition. These are created through somatic mutations. Researchers and physicians have recently used next-generation sequencing technology to detect neoantigens and develop tailored cancer immunotherapies. Neoantigens are short peptides derived from tumour-specific somatic mutations. These peptides bind to HLA (Human Leucocyte Antigen) molecule to be recognized by T-Cell Receptors (TCRs), which further activate the immune system for specific cancer cells. In manufacturing neoantigen-based vaccines, personalized neoantigen peptides are synthesized, which helps induce the T-cell population. This new type of immunotherapy can produce a strong and specific immune response and draw out stable therapeutic effects. As a result, personalized neoantigen peptide vaccines are designed to train a patient's immune system to target and kill tumour cells. Hence they are used to develop vaccines and immunotherapies against cancer cells. These significant neoantigens can control tumour outgrowth and felicitate cellular transformation.
Synthetic peptides are a recognized model of cancer vaccine delivery, but creating the peptides for each patient rapidly and inexpensively remains difficult. The rising number of clinical trials, the growth in cancer and chronic illness cases, and the necessity for long-term therapy for these diseases are all prominent market factors for Neoantigen peptide synthesis. Furthermore, advances in biotechnology research will help researchers better understand individualized neoantigen peptides. Increased external investment in cancer drug research and development, on the other hand, drives the market upward. On the other hand, costly designing and development of personalized cancer therapeutics and delayed clinical trials due to the COVID-19 impact will restrain the market.
The Neoantigen Peptides Manufacturing Market is segmented into the Scale of operations, end-users, and region. The scope of operation segment comprises research/preclinical, clinical, and commercial. The market is segmented into pharmaceutical/vaccine developer companies, contract research organizations (CRO), and academic & research institutes by end-users. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The North American market can witness rapid growth during the forecast period (2020-2030) due to the well-established healthcare infrastructure, growing research regarding Peptide synthesis, and the rising government efforts to develop personalized vaccines.
Major key players operating in the neoantigen peptide manufacturing market are CPC Scientific Inc, Polypeptide group, Genscript Biotech, Kaneka Eurogentec S.A., Vivitide, Almac, BCN Peptides, Creative Peptides, Pepscan, Provepharm, Creosalus, AnaSpec, Gyros Protein Technologies, Other Prominent Players
Companies Mentioned
- CPC Scientific Inc
- Polypeptide group
- Genscript Biotech
- Kaneka Eurogentec S.A.
- Vivitide
- Almac
- BCN Peptides
- Creative Peptides
- Pepscan
- Provepharm
- Creosalus
- Gyros Protein Technologies
- AnaSpec
- Other Prominent Players
Global Neoantigen Peptides Manufacturing Market, by End-Users 2020-2030 (Value US$ Mn)
